TE
ELVN icon

Tema ETFs’s Enliven Therapeutics ELVN Stock Holding History

Tema ETFs’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.08M Buy
60,694
+17,638
+41% +$749K 0.1% 146
2026
Q1 		$1.69M Buy
+43,056
New +$1.19M 0.11% 165
2025
Q4 		– Sell
-40,314
Closed -$825K – 575
2025
Q3 		$825K Buy
40,314
+7,735
+24% +$156K 0.07% 291
2025
Q2 		$654K Buy
32,579
+8,931
+38% +$169K 0.17% 123
2025
Q1 		$465K Buy
+23,648
New +$509K 0.14% 114

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Tema ETFs's ELVN Position: Q2 2026 in Review

Tema ETFs increased its Enliven Therapeutics (ELVN) stake by 41% in Q2 2026, buying an estimated $749K and bringing the position to 60,694 shares worth $3.08M. The position accounts for 0.1% of the portfolio, ranked #146.

Tema ETFs first reported a position in ELVN in Q1 2025 and has held it in 5 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Tema ETFs held 60,694 shares of Enliven Therapeutics worth $3.08M as of Q2 2026.
  • Tema ETFs bought 17,638 Enliven Therapeutics shares in Q2 2026, an estimated $749K.
  • Enliven Therapeutics made up 0.1% of Tema ETFs's portfolio in Q2 2026, its #146 holding.
  • Tema ETFs first reported a position in Enliven Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Tema ETFs's 13F filing for Q2 2026, filed 10 Jul 2026.